Project Grant R01HL175135
Award Date 9/1/25
Completion Date 6/30/29
Dollars Obligated $535K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- This $1,082,412 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research and development of tissue-engineered vascular grafts (TEVGs) using mesenchymal stem/stromal cells (MSCs) and extracellular vesicles (EVs). The University of Pittsburgh, the awardee, aims to optimize their silk scaffold-based TEVG construct seeded with EVs to advance it towards clinical translation. Key objectives include conducting in vitro...
- This federal Project Grant award of $740,037, funded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research on the regulation of angiogenesis (blood vessel formation) by cardiac fibroblasts following myocardial infarction. The key objectives are to investigate the temporal and spatial expression of pro- and anti-angiogenic factors secreted by cardiac fibroblasts to support cardiac repair and increase vascular...
- The federal Project Grant award, valued at $413,595, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports the development of a "Magnetic Rotational Platform for Coronary Lesions" by Unandup, LLC, a technology firm in St. Louis, Missouri. The project aims to create an innovative medical device technology that leverages magnetic fields to improve the treatment of severe coronary artery...
- This federal Project Grant award of $747,281 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of a real-time, non-invasive technique to characterize the mechanical properties of blood clots (thrombi) as they age. The project aims to utilize ultrasound-responsive nanodroplets that can transition into microbubbles when exposed to focused ultrasound, a process known as acoustic droplet vaporization (ADV). By leveraging ADV, the...
- This $298,368 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of a novel device for treating mitral valve regurgitation. The project aims to optimize the device design and procedure through bench testing, followed by acute in vivo studies to demonstrate the feasibility of the approach. The funding recipient, Link Medical LLC, has invented a catheter-based technology intended to restore proper mitral...
- The U.S. National Heart, Lung, and Blood Institute (NHLBI), through its Cardiovascular Diseases Research program (CFDA 93.837), awarded a $1,364,080 project grant to Vesteck, Inc. on September 15, 2025. The grant supports the development and feasibility testing of Vesteck's novel endovascular suturing device for augmenting endograft fixation during endovascular repair of abdominal aortic aneurysms (AAAs). The device aims to reduce reinterventions due to endograft migration or type 1A...
- This federal Project Grant award of $1,356,922.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of novel hydrogel-coated electrospun (HES) biomaterials for replacement heart valves. The key objectives are to: Identify optimal biomaterial and leaflet geometry characteristics to develop replacement heart valves with greater durability, resistance to thrombosis, and improved hemodynamics. This will leverage the...
- This Project Grant award from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $464,229 to Limax Biosciences Inc. to advance the development of their HEMOMAX biodegradable hydrogel sealant for use in vascular surgery. The key objectives are to: (1) conduct comprehensive bench performance testing, including sterilization validation and endotoxin assessment, and (2) evaluate the safety and efficacy of HEMOMAX in a...
- This $726,205 federal Project Grant awarded by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports the development and validation of a new super-resolution intravascular ultrasound (SR-IVUS) technology. The goal is to enable effective imaging of the coronary vasa vasorum network and thin fibrous cap of vulnerable atherosclerotic plaques to better assess plaque vulnerability and prevent acute coronary syndromes. The project involves creating an...
- The National Heart Lung and Blood Institute (NHLBI), part of the U.S. National Institutes of Health (NIH), awarded a $460,625 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Yale University on August 10, 2025. The objective of this project is to develop highly tunable and customizable Tissue Engineered Vascular Conduits (TEVCs) using a novel bioprinting method that can directly print fully physiological materials, including cell-laden tissues. The project aims...